Faron to Report Final Melanoma Survival Data from the MATINS Study ...
(PR-inside.com) Final data in PD-1 refractory metastatic melanoma underpin the rationale for the ongoing BLAZE trial of bexmarilimab in combination with nivolumab TURKU, FI / ACCESS Newswire / October 19, 2026 / Faron Pharmaceuticals Ltd. (HEL:FARON)(LSE:FARN), a global, clinical-stage biopharmaceutical company focused…
Short extract only — this publisher licenses its text. Read the full release at the source.
Free plan · Plus CA$29 or Pro CA$99/month


